GILDAnother oncology combo hits a wall
Gilead and MSD have decided to stop a Phase III study of Trodelvy combined with Keytruda after interim data apparently didn’t clear the “worth keeping alive” bar. In biotech, that’s the equivalent of getting halfway through a road trip and realizing the GPS has been lying to you the whole time.
Why this matters
Trodelvy has been one of Gilead’s more important oncology growth stories, so any stumble in a late-stage program gets attention fast. A failed or halted trial doesn’t just ding sentiment — it can shrink the list of future label-expansion dreams that bulls like to build into the stock.
The investor angle
A few things to keep in mind:
- Late-stage trial stops often mean the data weren’t good enough to justify more spending.
- Combination studies can be especially tricky because one drug can muddy the read on the other.
- Even if Trodelvy still has a path, losing momentum in a Phase III program can slow the oncology narrative.
Big picture: Gilead’s cancer ambitions still matter, but this is one of those “hope springs eternal, data does not” moments.